These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 27615008)
21. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Alkabbani W; Gamble JM Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473 [TBL] [Abstract][Full Text] [Related]
22. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A Diabetes Obes Metab; 2015 Mar; 17(3):304-8. PubMed ID: 24919820 [TBL] [Abstract][Full Text] [Related]
23. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Maegawa H; Tobe K; Tabuchi H; Nakamura I Expert Opin Pharmacother; 2016 Oct; 17(15):1985-94. PubMed ID: 27463414 [TBL] [Abstract][Full Text] [Related]
24. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H; J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746 [TBL] [Abstract][Full Text] [Related]
25. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192 [TBL] [Abstract][Full Text] [Related]
26. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy. Kutoh E; Wada A; Murayama T; Takizawa Y Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448 [TBL] [Abstract][Full Text] [Related]
27. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333 [TBL] [Abstract][Full Text] [Related]
28. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Takahashi K; Cho KY; Nakamura A; Miya A; Miyoshi A; Yamamoto C; Nomoto H; Niwa H; Takahashi K; Manda N; Kurihara Y; Aoki S; Ito YM; Atsumi T; Miyoshi H J Diabetes Investig; 2019 Mar; 10(2):429-438. PubMed ID: 30136403 [TBL] [Abstract][Full Text] [Related]
29. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Takase T; Nakamura A; Miyoshi H; Yamamoto C; Atsumi T Endocr J; 2017 Mar; 64(3):363-367. PubMed ID: 27980239 [TBL] [Abstract][Full Text] [Related]
30. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K; J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619 [TBL] [Abstract][Full Text] [Related]
32. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. Matsuba I; Kawata T; Iemitsu K; Asakura T; Amemiya H; Ishikawa M; Ito S; Kaneshiro M; Kanamori A; Kubota A; Shinoda K; Takai M; Takuma T; Takihata M; Takeda H; Tanaka K; Matsuzawa Y; Machimura H; Minagawa F; Minami N; Mokubo A; Miyakawa M; Terauchi Y; Tanaka Y J Diabetes Investig; 2020 Sep; 11(5):1248-1257. PubMed ID: 32149469 [TBL] [Abstract][Full Text] [Related]
33. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548 [TBL] [Abstract][Full Text] [Related]
35. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial. Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517 [TBL] [Abstract][Full Text] [Related]
36. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study. Maegawa H; Tobe K; Nakamura I; Uno S Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926 [No Abstract] [Full Text] [Related]
37. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Wilding JP; Ferrannini E; Fonseca VA; Wilpshaar W; Dhanjal P; Houzer A Diabetes Obes Metab; 2013 May; 15(5):403-9. PubMed ID: 23163880 [TBL] [Abstract][Full Text] [Related]
38. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Ferrannini E; Veltkamp SA; Smulders RA; Kadokura T Diabetes Care; 2013 May; 36(5):1260-5. PubMed ID: 23359360 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822 [TBL] [Abstract][Full Text] [Related]
40. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Parveen R; Hussain S; Saini S; Khan P; Saha N; Nidhi Expert Opin Pharmacother; 2024 May; 25(7):925-935. PubMed ID: 38804904 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]